Abstract
Reperfusion of ischemic brain is associated with production of thromboxane A2 (TXA2), a proaggregatory vasoconstrictor. We used an animal model of transient forebrain ischemia to study the effects of 1-benzylimidazole (1-BI), a selective inhibitor of thromboxane synthase, upon cerebral elcosanoid levels and cerebral blood flow. Male Wistar rats were subjected to 30 minutes of four-vessel occlusion. The mean±SEM brain level of TXB2, the stable metabolite of TXA2, determined after 60 minutes of reperfusion was 101±20 pg/mg brain protein in five ischemic control rats. Infusion of 10 μg/g 1-BI reduced mean±SEM cerebral TXB2 concentration to 11±3 pg/mg brain protein in five rats (p≤0.002). Mean±SEM hemispheric cerebral blood flow measured in four ischemic control rats after 60 minutes of reperfusion was 42±9 ml/100 g brain/min compared with 104±13 ml/100 g brain/min in three 1-BI-treated rats (p≤0.001). Mean±SEM hippocampal blood flow in four ischemic control rats after 60 minutes of reperfusion was 51±14 ml/100 g brain/min compared with 125±25 ml/100 g brain/min in three 1-BI-treated rats (p≤0.04). We conclude that selective inhibition of thromboxane synthase may alleviate ischemic brain damage by reducing cerebral TXA2 concentrations and elevating cerebral blood flow.
Original language | English |
---|---|
Pages (from-to) | 627-632 |
Number of pages | 6 |
Journal | Stroke |
Volume | 20 |
Issue number | 5 |
DOIs | |
State | Published - May 1989 |
Keywords
- Cerebral blood flow
- Cerebral ischemia
- Rats
- Thromboxane synthase
ASJC Scopus subject areas
- Clinical Neurology
- Cardiology and Cardiovascular Medicine
- Advanced and Specialized Nursing